Skip to main content

Table 1 Patient characteristics

From: The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study

Characteristic

Number

Percent

All Patients

66

100

Age (years) Median (min, max)

72 (57, 93)

 

PSA (ng/ml)—Median (min, max)

31.5 (1.0,64.0)

 

Ethnicity

 Non-White

9

13.6

 White

57

86.4

Body Mass Index

 Underweight (<18.5)

1

1.5

 Normal (18.5–24.9)

13

19.7

 Overweight (25.0–29.9)

25

37.9

 Obese

14

21.2

 Not Available

13

19.7

Diabetes

 No

62

93.9

 Yes

4

6.1

Performance Status

 PS 0

31

47.0

 PS1-2

35

53.0

Gleason score

 5–6

2

3.0

 7

11

16.7

 8–10

51

77.3

 Missing

2

3.0

Metastatic Volume

 Low

31

47.0

 High

35

53.0

Treatment Arm

 ADT

34

51.5

 ADT + Chemo

31

47.0

 Not Available

1

1.5

  1. ADT Androgen Deprivation Therapy, Chemo Chemotherapy